ProCE Banner Activity

ALEX: Alectinib vs Crizotinib as First-line Therapy in Pts With ALK+ NSCLC

Slideset Download
Conference Coverage
Alectinib increased median PFS more than 2-fold and delayed CNS progression with favorable toxicity compared with crizotinib.

Released: June 08, 2017

Expiration: June 07, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology